NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
Clinical Trials
14 trialsNCT07310173 2025-12-30
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 2 Recruiting
NCT06902246 2025-12-02
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT05194293 2025-09-04
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT07100392 2025-08-17
LEAF-02
Fudan University
Phase 2 Recruiting
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT04310709 2022-12-06
RENOBATE
Asan Medical Center
Phase 2 Completed
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04476329 2021-12-30
ReDos HCC
SC Liver Research Consortium, LLC
Phase 2 Terminated
NCT01003015 2015-04-03
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
Bayer
Phase 2 Completed